EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology

Nikolai V Naoumov iD, David E Kleiner iD, Elaine Chng, Dominique Brees, Chandra Saravanan iD, Yayun Ren, Dean Tai, Arun J Sanyal iD

Liver International · 2024

DOI: 10.1111/liv.16092 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Liver International, 2024. Verfasst von Nikolai V Naoumov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicine, University College London, London, UK. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Novartis Pharma AG, HistoIndex Pte. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Metabolic dysfunction‐associated steatohepatitis (MASH) with bridging fibrosis is a critical stage in the evolution of fatty liver disease. Second harmonic generation/two‐photon excitation fluorescence (SHG/TPEF) microscopy with artificial intelligence (AI) provides sensitive and reproducible quantitation of liver fibrosis. This methodology was applied to gain an in‐depth understanding of intra‐stage fibrosis changes and septa analyses in a homogenous, well‐characterised group with MASH F3 fibrosis.

Methods

Paired liver biopsies (baseline [BL] and end of treatment [EOT]) of 57 patients (placebo, n = 17 and tropifexor n = 40), with F3 fibrosis stage at BL according to the clinical research network (CRN) scoring, were included. Unstained sections were examined using SHG/TPEF microscopy with AI. Changes in liver fibrosis overall and in five areas of liver lobules were quantitatively assessed by qFibrosis. Progressive, regressive septa, and 12 septa parameters were quantitatively analysed. Results qFibrosis demonstrated fibrosis progression or regression in 14/17 (82%) patients receiving placebo, while the CRN scoring categorised 11/17 (65%) as ‘no change’. Radar maps with qFibrosis readouts visualised quantitative fibrosis dynamics in different areas of liver lobules even in cases categorised as ‘No Change’. Measurement of septa parameters objectively differentiated regressive and progressive septa ( p < .001). Quantitative changes in individual septa parameters (BL to EOT) were observed both in the ‘no change’ and the ‘regression’ subgroups, as defined by the CRN scoring.

Conclusion

SHG/TPEF microscopy with AI provides greater granularity and precision in assessing fibrosis dynamics in patients with bridging fibrosis, thus advancing knowledge development of fibrosis evolution in natural history and in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisLiverHumansMaleFemaleBiopsyMiddle AgedArtificial IntelligenceMicroscopy, Fluorescence, MultiphotonDisease ProgressionFatty LiverAdult

Stichwörter der Autor:innen

digital pathology with artificial intelligenceliver fibrosismetabolic dysfunction‐associated steatohepatitisquantitative assessment fibrosis regressionsecond harmonic generation microscopy

Autor:innen und Institutionen

  • Division of Medicine, University College London, London, UK.
  • Laboratory of Pathology, Post-Mortem Section, National Cancer Institute, Bethesda, Maryland, USA.
  • Histoindex Pte. Ltd., Singapore, Singapore.
  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Institute of Biomedical Research, Cambridge, Massachusetts, USA.
  • Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.

ORCID-Profile: Nikolai V Naoumov, David E Kleiner, Chandra Saravanan, Arun J Sanyal

Förderung

  • Intramural NIH HHS
  • Novartis Pharma AG
  • HistoIndex Pte. Ltd
  • National Institutes of Health, National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Naoumov, N. V., Kleiner, D. E., Chng, E., Brees, D., Saravanan, C., Ren, Y., Tai, D., & Sanyal, A. J. (2024). Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology. Liver International. https://doi.org/10.1111/liv.16092

Vancouver

Naoumov NV, Kleiner DE, Chng E, Brees D, Saravanan C, Ren Y, et al. Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology. Liver International. 2024. doi:10.1111/liv.16092

BibTeX
@article{Naoumov2024,
  author = {Naoumov, Nikolai V and Kleiner, David E and Chng, Elaine and Brees, Dominique and Saravanan, Chandra and Ren, Yayun and Tai, Dean and Sanyal, Arun J},
  title = {Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.16092}
}
Kostenlos starten →